Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2024 | Other Grant/Funding Number | Rome Foundation | |
| APP2025943 | Other Grant/Funding Number | NHMRC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Monash University | OTHER |
Not provided
Not provided
Not provided
Not provided
This research project will assess how two treatments for irritable bowel syndrome (one dietary and one behavioral) work and for whom. This will be done by assessing moderators (what treatment works for who and in what context) and mediators (how treatment works). Investigators will also assess how the diet and behavioral treatments affect IBS symptoms during treatment. Participants will be randomized to either: i. A FODMAP diet online program that focuses on modifying the consumption of foods high or moderate in fermentable carbohydrates (FODMAPS) to manage IBS symptoms. or, ii. An Exposure-based Cognitive Behavioral Therapy (E-CBT) online program for IBS that focuses on changing symptom-related behaviors which are known to worsen IBS symptoms.
This research uses a randomized controlled trial to investigate the treatment of irritable bowel syndrome (IBS). A range of treatments for IBS are available, but each work for only a portion of patients, and it is unclear why. This research project will assess how two treatments (one dietary and one behavioral) work and for whom. Investigators will do this by assessing moderators (what treatment works for who and in what context) and mediators (how treatment works). This project will also assess how the diet and behavioral treatments affect IBS symptoms during treatment. Participants will be randomized to either: i. A FODMAP diet online program that focuses on modifying the consumption of foods high or moderate in fermentable carbohydrates (FODMAPS) to manage IBS symptoms. This treatment involves 3-phases: FODMAP restriction (phase 1), FODMAP re-introduction (phase 2), and FODMAP personalization (phase 3), or, ii. An Exposure-based Cognitive Behavioral Therapy (E-CBT) online program for IBS that focuses on symptom-related behaviors such as avoidance of activities and foods, excessive toilet visits, and behaviors to control symptoms which are known to worsen IBS symptoms. E-CBT uses daily self-observation and exposure exercises to change these behaviors to relieve IBS symptoms. Investigators believe that both treatments, FODMAP diet and E-CBT, will lead to an improvement in IBS gastrointestinal symptoms. Primary moderators and mediators to be assessed include gastrointestinal symptom anxiety, food avoidance behaviour and FODMAP intake.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| FODMAP Diet | Experimental | Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) Diet is a 12-week online intervention with dietitian support. |
|
| Exposure-based Cognitive Behavioral Therapy (E-CBT) | Experimental | Exposure-based Cognitive Behavioral Therapy is a 12-week online intervention with psychologist support. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FODMAP Diet | Other | The intervention is an online diet program. The diet is the low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet. It is a 3-phase diet which involves: 1.Phase 1 FODMAP restriction: restrict foods high or moderate in FODMAPs and swap these for low FODMAP alternatives; 2. Phase 2 FODMAP reintroduction: continue to follow a low FODMAP diet and complete a series of food challenges to understand which foods and FODMAPs are tolerated and which trigger symptoms; 3. Phase 3 FODMAP personalization: include well-tolerated foods and FODMAPs back into the diet, and restrict poorly tolerated foods and FODMAPs to a level needed to maintain symptom relief. The online FODMAP program is a self-directed diet program with support from an online clinician (Accredited Practicing Dietitian [APD]). The content is delivered over 12 weeks. After each module participants will complete homework activities and questions and submit them to the dietitian for feedback. |
| Measure | Description | Time Frame |
|---|---|---|
| Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome (GSRS-IBS ) | The GSRS-IBS is a 13-item measure of IBS symptom severity to reflect the last 7 days. The items are scored between 1 (no discomfort at all) and 7 (very severe discomfort), rendering a total score between 13 and 91. | Measured weekly between baseline (prior to intervention) and after intervention completed (week 12). |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) | The GSRS-IBS is a 13-item measure of IBS symptom severity to reflect the last 7 days. The items are scored between 1 (no discomfort at all) and 7 (very severe discomfort), rendering a total score between 13 and 91. | Baseline and 3-and 6 month follow up time points after intervention completed (week 12). |
| Measure | Description | Time Frame |
|---|---|---|
| Gastrointestinal Specific Anxiety (GSA) measured using Visceral Sensitivity Index (VSI) | The VSI is a 15-item measure of gastrointestinal-specific anxiety, scored on a Likert scale of 1 to 6 with 1=strongly agree; 2=moderately agree; 3=mildly agree; 4=mildly disagree; 5=moderately disagree and 6=strongly disagree. The VSI is being measured as a putative mediator. | VSI will be measured 2nd weekly between baseline (prior to intervention), after intervention (week 12) and and at follow up timepoints of 3-and 6 months following the 12-week intervention as a putative mediator. |
Inclusion Criteria: Each participant must meet all of the following criteria to be enrolled in this trial:
Exclusion Criteria:Patients meeting any of the following criteria will be excluded from the trial:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jessica Biesiekierski, A/Prof | Contact | +61 499 272 673 | jessica.biesiekierski@unimelb.edu.au | |
| Jacqueline L Anderson, APD | Contact | jacquia@student.unimelb.edu.au |
| Name | Affiliation | Role |
|---|---|---|
| Associate Professor Jessica Biesiekierski | University of Melbourne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Melbourne | Recruiting | Melbourne | Victoria | 3010 | Australia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35775328 | Background | Biesiekierski JR, Manning LP, Murray HB, Vlaeyen JWS, Ljotsson B, Van Oudenhove L. Review article: exclude or expose? The paradox of conceptually opposite treatments for irritable bowel syndrome. Aliment Pharmacol Ther. 2022 Aug;56(4):592-605. doi: 10.1111/apt.17111. Epub 2022 Jul 1. |
Not provided
Not provided
Potential data shared includes:
The IPD and supporting information will be available beginning 3 months following analysis and article publication for 15 years.
The IPD and supporting information will be made available for use by future researchers from a recognized research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept University of Melbourne conditions for access.
Not provided
| ID | Term |
|---|---|
| D043183 | Irritable Bowel Syndrome |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| ID | Term |
|---|---|
| D003109 | Colonic Diseases, Functional |
| D003108 | Colonic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000092622 | FODMAP Diet |
| ID | Term |
|---|---|
| D000092724 | Elimination Diets |
| D004032 | Diet |
| D009747 | Nutritional Physiological Phenomena |
| D000066888 | Diet, Food, and Nutrition |
Not provided
Not provided
Participants will be randomized to one of two treatment arms. The randomization schedule will be generated using http://www.randomization.com. Participants will be stratified by site (Australia or US) before randomization.
Not provided
Not provided
The people analyzing the results/data will be masked
|
| Exposure-based Cognitive Behavioral Therapy | Behavioral | The intervention is an online behavioral therapy program. The behavioral therapy is Exposure-based Cognitive Behavioral Therapy (E-CBT) Program. The E-CBT program is organised into six steps to be completed over 12 weekly modules with support from an online clinician (Psychologist). The first step contains a rationale for the treatment and instructions on self-observation. Steps 2, 3 and 4 contain a presentation of a psychological model of IBS and continued self-observation exercises. The fifth step covers exposure exercises, divided into three categories; (1) exercises that provoke symptoms, (2) abolishment of behaviors that serve to control symptoms, (3) exposure to situations where symptoms were unwanted. The final step (Step 6) includes how to handle relapses into avoidance behaviors and how to maintain a widened behavioral repertoire. After each module participants will be directed to complete homework activities and questions and submit them to the psychologist for feedback. |
|
| Change from baseline in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) questionnaire | The IBS-SSS is a 5-item measure of the severity of IBS symptoms: frequency and severity of abdominal pain, severity of bloating, dissatisfaction with bowel habits and impact on life in general. Questions ask about IBS and gut symptoms during the past 7 days except question 4 which asks participants to enter the number of days they get pain in every 10. days. A total score ranging from 0 to 500. Mild, moderate and severe cases are indicated by scores of 75 to <175, 175 to <300 and >300 respectively | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in IBS quality of life (IBS-QOL) questionnaire | IBS-QOL is used to assess the impact on quality of life for patients with IBS and consists of 34 items scored between 1 and 5, resulting in a maximum score of 170. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in Nine Item ARFID (Avoidant Restrictive Food Intake Disorder) Screen (NIAS) questionnaire | NIAS is a 9-item measure of ARFID symptoms. The scale has 9 questions, scored from 0 (strongly disagree) to 5 (strongly agree) and summed into three subscales (fear of adverse consequences, lack of interest/appetite, and sensory sensitivity); each range = 0-15), with higher scores indicating greater severity. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in Fear of Food Questionnaire (FFQ) questionnaire | The Fear of Food Questionnaire (FFQ) is an 18-item measure of food-related fears averaged into five subscales (GI fears, food fears, food avoidance, social impairment, and distress/loss of pleasure) and a total score between 0 and 90 (each range = 0-5), with higher scores indicating greater food related fears. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in Patient Health Questionnaire-12 (PHQ-12) (derived from PHQ-15) questionnaire | PHQ-15 is a validated measure of somatization. Questions reflect the previous 4 weeks. It comprises 15 somatic symptoms with each symptom scored from 0 ("not bothered at all") to 2 ("bothered a lot"). The PHQ-15 will be administered to facilitate assessment of PHQ-12. The PHQ-12 is a commonly used modification of the PHQ-15 without three GI-related items; constipation, loose bowels, or diarrhea; nausea, gas, or indigestion. The PHQ-12 represents non-GI or extraintestinal somatic symptoms. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in Generalized anxiety disorder (GAD-7) questionnaire | GAD-7 is a 7-item questionnaire used for screening and measuring the severity of anxiety symptoms. Questions reflect the previous 14 days and responses are measured on a 4-point Likert scale; 0=not at all sure; 1=several days; 2=more than half the days; 3=nearly every day. Total GAD-7 scores range from 0-21 with higher scores indicating greater severity of symptoms. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in Patient Health Questionnaire (PHQ-9) questionnaire | The Patient Health Questionnaire (PHQ-9) is a 9-item measure of depression severity. Questions reflect the previous 14 days. Each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day) and severity score can range from 0 to 27. PHQ-9 scores of 5, 10, 15, and 20 indicate mild, moderate, moderately severe, and severe depression, respectively. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in Gastrointestinal Specific Anxiety (GSA) measured using Visceral Sensitivity Index (VSI) | The VSI is a 15-item measure of gastrointestinal-specific anxiety, scored on a Likert scale of 1 to 6 with 1=strongly agree; 2=moderately agree; 3=mildly agree; 4=mildly disagree; 5=moderately disagree and 6=strongly disagree. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in Avoidance behavior measured using Irritable Bowel Syndrome-Behavioural Responses Questionnaire (IBS-BRQ) | IBS-BRQ is a 26-item measure of avoidance behavior. The scale has 26 items, scored from 1 (never) to 7 (always), indicating how persistently the particular avoidance or toilet behavior is carried out. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in Total FODMAP intake measured using 3-day food diary | Participants will record their food intake for 3 days (including one weekend day) using paper or an app. Total FODMAP intake will be calculated g/day. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Change from baseline in stool frequency and consistency using 7-day stool diary based on Bristol Stool Form Scale (BSFS) | The stool diary will be completed over 7 days and is based on the Bristol Stool Form Scale (BSFS) for IBS subtyping and bowel habit assessment i.e. stool frequency and consistency. Stool consistency will be quantified according to ROME classifications. | Baseline, after intervention completed (week 12), and at follow up time points of 3-and 6 months following the 12-week intervention. |
| Gastrointestinal microbiome composition and function using stool sample using OMNIgene GUT | Gut microbiome composition (i.e., alpha diversity, beta diversity, relative abundance) and function 16S rRNA and shotgun sequencing. Measured as exploratory mediators. | Gastrointestinal microbiome composition and function will be measured 2nd weekly between baseline (prior to intervention) and after intervention completed (week 12) as exploratory mediators. |
| Individual FODMAPs' intake using 3-day food diary | Participants will record their food intake for 3 days (including one weekend day) using paper or an app. Individual FODMAPs' intake will be calculated g/day. Measured as exploratory mediators. | Will be measured 2nd weekly between baseline (prior to intervention) and after intervention completed (week 12) as exploratory mediators. |
| Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome GSRS-IBS | The GSRS-IBS is a 13-item measure of IBS symptom severity to reflect the last 7 days. The items are scored between 1 (no discomfort at all) and 7 (very severe discomfort), rendering a total score between 13 and 91. Measured as an exploratory moderator. | Baseline (prior to start of intervention) as an exploratory moderator. |
| IBS quality of life (IBS-QOL) questionnaire | Description: I IBS-QOL is used to assess the impact on quality of life for patients with IBS and consists of 34 items scored between 1 and 5, resulting in a maximum score of 170. Measured as an exploratory moderator. | Baseline (prior to start of intervention) as an exploratory moderator. |
| Fear of Food Questionnaire (FFQ) questionnaire | The Fear of Food Questionnaire (FFQ) is an 18-item measure of food-related fears averaged into five subscales (GI fears, food fears, food avoidance, social impairment, and distress/loss of pleasure) and a total score between 0 and 90 (each range = 0-5), with higher scores indicating greater food related fears. Measured as an exploratory moderator. | Baseline (prior to start of intervention) as an exploratory moderator. |
| Nine Item ARFID (Avoidant Restrictive Food Intake Disorder) Screen (NIAS) questionnaire | NIAS is a 9-item measure of ARFID symptoms. The scale has 9 questions, scored from 0 (strongly disagree) to 5 (strongly agree) and summed into three subscales (fear of adverse consequences, lack of interest/appetite, and sensory sensitivity); each range = 0-15), with higher scores indicating greater severity. Measured as an exploratory moderator. | Baseline (prior to start of intervention) as an exploratory moderator. |
| Patient Health Questionnaire-12 (PHQ-12) (derived from PHQ-15) questionnaire | PHQ-15 is a validated measure of somatization. Questions reflect the previous 4 weeks. It comprises 15 somatic symptoms with each symptom scored from 0 ("not bothered at all") to 2 ("bothered a lot"). The PHQ-15 will be administered to facilitate assessment of PHQ-12. The PHQ-12 is a commonly used modification of the PHQ-15 without three GI-related items; constipation, loose bowels, or diarrhea; nausea, gas, or indigestion. The PHQ-12 represents non-GI or extraintestinal somatic symptoms. Measured as an exploratory moderator. | Baseline (prior to start of intervention) as an exploratory moderator. |
| Patient Health Questionnaire (PHQ-9) questionnaire | The Patient Health Questionnaire (PHQ-9) is a 9-item measure of depression severity. Questions reflect the previous 14 days. Each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day) and severity score can range from 0 to 27. PHQ-9 scores of 5, 10, 15, and 20 indicate mild, moderate, moderately severe, and severe depression, respectively. Measured as an exploratory moderator. | Baseline (prior to start of intervention) as an exploratory moderator. |
| Generalized anxiety disorder (GAD-7) questionnaire | GAD-7 is a 7-item questionnaire used for screening and measuring the severity of anxiety symptoms. Questions reflect the previous 14 days and responses are measured on a 4-point Likert scale; 0=not at all sure; 1=several days; 2=more than half the days; 3=nearly every day. Total GAD-7 scores range from 0-21 with higher scores indicating greater severity of symptoms. Measured as an exploratory moderator. | Baseline (prior to start of intervention) as an exploratory moderator. |
| Gastrointestinal microbiome composition and function using stool sample using a stool sample collection kit. | Gut microbiome composition (i.e., alpha diversity, beta diversity, relative abundance) and function 16S rRNA and shotgun sequencing . Measured as an exploratory moderator. | Baseline (prior to start of intervention) as an exploratory moderator. |
| IBS subtype using 7-day stool diary based on Bristol Stool Form Scale (BSFS). | The stool diary will be completed over 7 days and is based on the Bristol Stool Form Scale (BSFS) for IBS subtyping and bowel habit assessment i.e. stool frequency and consistency. Stool consistency will be quantified according to ROME classifications. Measured as a exploratory moderator. | Baseline (prior to start of intervention) as an exploratory moderator. |
| Client Satisfaction Questionnaire | The Client Satisfaction Questionnaire is an 8-question brief global measure of client satisfaction. The eight questions are measured on a 4-point Likert scale with questions 1, 3, 6 and 7 measured on a positive scale and questions 2, 4, 5 and 8 on a negative scale. Total scores range from 8 to 32, with the higher number indicating greater satisfaction. | End of the 12-week intervention and at 3-and 6 months follow up time points after 12-week intervention.. |
| Proportion of participants who achieve a change from baseline in Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) of ≥30% total score | The GSRS-IBS is a 13-item measure of IBS symptom severity to reflect the last 7 days. The items are scored between 1 (no discomfort at all) and 7 (very severe discomfort), rendering a total score between 13 and 91. | Baseline and after intervention completed (week 12) |
| Proportion of participants who achieve a change from baseline in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) of ≥50 points total score. | The IBS-SSS is a 5-item measure of the severity of IBS symptoms: frequency and severity of abdominal pain, severity of bloating, dissatisfaction with bowel habits and impact on life in general. Questions ask about IBS and gut symptoms during the past 7 days with the exception of question 4 which asks participants to enter the number of days they get pain in every 10. days. A total score ranging from 0 to 500. Mild, moderate and severe cases are indicated by scores of 75 to <175, 175 to <300 and >300 respectively | Baseline and after intervention completed (week 12) |
| Avoidance behavior measured using Irritable Bowel Syndrome-Behavioural Responses Questionnaire (IBS-BRQ) | IBS-BRQ is a 26-item measure of avoidance behavior. The scale has 26 items, scored from 1 (never) to 7 (always), indicating how persistently the particular avoidance or toilet behavior is carried out. IBS-BRQ is measured as a putative mediator. | IBS-BRQ will be measured 2nd weekly between baseline (prior to intervention), after intervention (week 12) and and at follow up timepoints of 3-and 6 months following the 12-week intervention as a putative mediator. |
| Total FODMAP intake measured using 3-day food diary | Participants will record their food intake for 3 days (including one weekend day) using paper or an app. Total FODMAP intake will be calculated g/day. Total FODMAP intake is being measured as a putative mediator. | Total FODMAP intake will be measured 2nd weekly between baseline (prior to intervention), after intervention (week 12) and and at follow up timepoints of 3-and 6 months following the 12-week intervention as a putative mediator. |
| Treatment preference | Baseline treatment preference will be assessed with a single question prior to randomization: "If you had a choice, which treatment would you prefer to receive?". Three response options will be provided: FODMAP diet program; Cognitive Behavioral Therapy program; No preference. Measured as a putative moderator. | Baseline (prior to start of intervention) as a putative moderator. |
| Gastrointestinal Specific Anxiety (GSA) measured using Visceral Sensitivity Index (VSI) | The VSI is a 15-item measure of gastrointestinal-specific anxiety, scored on a Likert scale of 1 to 6 with 1=strongly agree; 2=moderately agree; 3=mildly agree; 4=mildly disagree; 5=moderately disagree and 6=strongly disagree. The VSI is being measured as a putative moderator. | Baseline (prior to start of intervention) as a putative moderator. |
| Avoidance behavior measured using Irritable Bowel Syndrome-Behavioural Responses Questionnaire (IBS-BRQ) | IBS-BRQ is a 26-item measure of avoidance behavior. The scale has 26 items, scored from 1 (never) to 7 (always), indicating how persistently the particular avoidance or toilet behavior is carried out. IBS-BRQ is measured as a putative moderator. | Baseline (prior to start of intervention) as a putative moderator. |
| Total FODMAP intake measured using 3-day food diary | Participants will record their food intake for 3 days (including one weekend day) using paper or an app. Total FODMAP intake will be calculated g/day. Total FODMAP intake is being measured as a putative mediator. Measured as a putative moderator. | Baseline (prior to start of intervention) as a putative moderator. |
| Credibility expectancy questionnaire (CEQ) questionnaire | The Credibility & Expectancy Questionnaire is a 6-question measure of treatment expectancy and credibility. Credibility is derived from the first three 'think' (cognitively based) questions and expectancy is derived from the fourth 'think' question and the two 'feel' (affectively based) questions. Measured as a control variable. | End of week 2 of 12-week intervention |
| Working alliance inventory for guided internet intervention (WAI-I) questionnaire | The Working Alliance Inventory for guided Internet interventions (WAI-I) is a 12 item tool to evaluate the working alliance in the context of guided Internet interventions. It consists of two subscale dimensions; Dimension 1: task and goal agreement with the program; and Dimension 2: bond with therapist. Items are rated on a 5-point Likert scale ranging from 1 (never) to 5 (always) and will be reported as a total score. Measured as a control variable. | End of week 2 of 12-week intervention |
| D010829 | Physiological Phenomena |